NRIX 最新10-Q变化
将 NRIX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-09 与上一份 10-Q · 2026-04-08
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +7 | −3 | ~36 | 56 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~3 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | +5 | −4 | ~59 | 477 |
| 其他信息 | 文字有新增/删除 | +1 | −3 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-09
On June 6, 2026, we entered into the Roche Collaboration Agreement to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948). Under the terms of the Roche Collaboration Agreement, we will receive an upfront cash payment of $700.0 million and are eligible to receive developm…
Our collaboration revenue decreased by $5.0 million and $17.2 million during the three and six months ended May 31, 2026, compared to the three and six months ended May 31, 2025, respectively. For all periods presented, the decrease in revenue from our collaborations with Gilead and Sanofi was prima…
Our license revenue was $30.0 million for the three and six months ended May 31, 2025 and is related to the Sanofi License Extensions. There was no license revenue for the three and six months ended May 31, 2026.
Our research and development expenses increased by $9.6 million during the three months ended May 31, 2026, compared to the three months ended May 31, 2025. There was an increase in clinical, contract manufacturing and consulting costs as we continued to accelerate the enrollment of patients in the …
Our research and development expenses increased by $24.0 million during the six months ended May 31, 2026, compared to the six months ended May 31, 2025. There was an increase in clinical, contract manufacturing and consulting costs as we continued to accelerate the enrollment of patients in the ong…
相对上期删除的文字 · 来源:10-Q · 2026-04-08
Our collaboration revenue decreased by $12.2 million during the three months ended February 28, 2026, compared to the three months ended February 28, 2025, primarily due to decreased revenue from our collaboration with Sanofi as we concluded the initial research term for certain drug targets. The de…
Our research and development expenses increased by $14.5 million during the three months ended February 28, 2026, compared to the three months ended February 28, 2025. There was an increase in clinical, contract manufacturing and consulting costs as we continued to accelerate the enrollment of patie…
Our general and administrative expenses increased by $3.0 million during the three months ended February 28, 2026, compared to the three months ended February 28, 2025. There was an increase in compensation and related personnel costs due to an increase in headcount.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-07-09
The Roche Collaboration Agreement is subject to closing conditions and may not close when expected or at all, and we may fail to realize all of the anticipated benefits.
In June 2026, we entered into the Roche Collaboration Agreement for the co-development and co-commercialization of bexobrutideg. The closing of the Roche Collaboration Agreement is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under…
It is unclear how future regulatory actions to implement the IRA may affect our products and future profitability. Although in May 2026 the Supreme Court declined to hear certain manufacturer challenges to the IRA price negotiation program, other litigation remains pending, the outcome of which coul…
The current presidential administration has also signaled its intent to pursue additional healthcare reform measures, including those aimed at reducing prescription drug prices, through various means, including presidential executive orders and agency action. These efforts include, among other thing…
In addition, as referenced above, states have shown an increased interest in regulating the processing of personal information in general and specifically in the privacy of health data. Washington state passed the My Health My Data Act, which took effect on March 31, 2024, and is focused on the coll…
相对上期删除的文字 · 来源:10-Q · 2026-04-08
It is unclear how future regulatory actions to implement the IRA, as well as the outcome of pending litigation against the IRA, may affect our products and future profitability, and we cannot predict the likelihood, nature, or extent of other health reform initiatives that may arise from future legi…
Moreover, recent healthcare regulatory developments indicate that prescription drug price reduction remains a key policy objective for the current presidential administration. The current presidential administration has also signaled its intent to pursue additional healthcare reform measures, includ…
In addition, states have shown an increased interest in regulating the processing of personal information in general and specifically in the privacy of health data. Washington state passed the My Health My Data Act, which took effect on March 31, 2024, and is focused on the collection of consumer he…
Under the UK GDPR, companies not established in the UK but who process personal data in relation to the offering of goods or services to individuals in the UK, or to the monitoring of the behavior of individuals in the UK, will be subject to the UK GDPR. On December 19, 2025, the European Commission…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-09
No director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended May 31, 2026.
相对上期删除的文字 · 来源:10-Q · 2026-04-08
On February 3, 2026, Hans van Houte, Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 173,860…
On February 27, 2026, Gwenn M. Hansen, Chief Scientific Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Hansen Plan), providing for the potential sale of up to 52,460 …
No other director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended February 28, 2026.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议